A look ahead at this week in women's health from Contemporary OB/GYN:
At ACR Convergence 2022, Hyun Son, PharmD, discussed the role of the FDA’s Drug Shortage Staff in preventing and mitigating drug shortages.
Cleveland Clinic begins charging for doctors’ time spent responding to some electronic messages
At ACR Convergence 2022, Amit Golding, MD, PhD, outlined drugs recently approved by the FDA, and discussed the requirements for biosimilars to meet approval.
Exposure to more than 100 mg was linked to significantly lower odds ratios for first-ever ACS event for women.
The association between type of body composition and fibromyalgia was evaluated using 43 women with clinically diagnosed fibromyalgia.
Check back soon for additional updates.
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More
IUD placement within 48 hours nonsuperior vs 2 to 4 weeks after abortion
November 19th 2024A study reveals no significant difference in 6-month intrauterine device use between placements within 48 hours or 2 to 4 weeks after a second-trimester abortion, though earlier placement carries a higher expulsion risk.
Read More